Achieve Life Sciences (ACHV) vs Kura Oncology (KURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed Kura Oncology (KURA) over the past year, gaining 51.9% versus a loss of 7.7%. Over five years, ACHV leads with a -20.4% price change compared with -48.3% for KURA. Kura Oncology is the larger company by market cap ($807.8 million vs $657.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | KURA |
|---|---|---|
| Share price | $6.38 | $9.08 |
| Market cap | $657.79M | $807.76M |
| 1-day change | -8.46% | -6.39% |
| YTD return | +28.37% | -12.61% |
| 1-year return | +51.90% | -7.72% |
| 5-year return | -20.45% | -48.29% |
| EPS (TTM) | $-1.69 | $-3.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $67.48M |
| Revenue growth (YoY) | — | +25.24% |
| Net income (latest FY) | $-54.65M | $-278.67M |
| Operating margin | — | -449.94% |
| Net margin | — | -412.95% |
| 52-week high | $8.64 | $13.90 |
| 52-week low | $2.62 | $7.36 |
| Distance from 52-week high | -26.16% | -34.68% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +121.79% | +250.77% |
| Average volume | 1.41M | 1.82M |
| Shares outstanding | 103.10M | 88.96M |
| Employees | 28 | 260 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACHV has outperformed KURA by 59.6 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Healthcare · Biotechnology · 28 employees
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Healthcare · Biotechnology · 260 employees
ACHV vs KURA FAQ
Which is bigger, Achieve Life Sciences or Kura Oncology?
Kura Oncology (KURA) is larger, with a market capitalization of $807.76M compared with $657.79M for Achieve Life Sciences (ACHV).
Which stock has performed better over the past year, ACHV or KURA?
ACHV returned +51.90% over the past 12 months, compared with -7.72% for KURA (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and Kura Oncology in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.